| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
140,990,000 |
| Market
Cap: |
73.88(M) |
| Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
| 52
Week Range: |
$0.2971 - $1.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
11,784 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,025 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
| Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Smith Karen L. |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
25,700 |
|
- |
|
| Macrae Sandy |
President and CEO |
• • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
138,375 |
347,066 |
|
- |
|
| Macrae Sandy |
President and CEO |
• • – |
2021-02-25 |
4 |
D |
$11.19 |
$395,130 |
D/D |
(35,311) |
208,691 |
|
- |
|
| Loeb Gary |
EVP, General Counsel & Sec. |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
44,000 |
88,781 |
|
- |
|
| Loeb Gary |
EVP, General Counsel & Sec. |
• – – |
2021-02-25 |
4 |
D |
$11.19 |
$64,477 |
D/D |
(5,762) |
44,781 |
|
- |
|
| Duraibabu Prathyusha |
VP Principal Acct. Officer |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
41,135 |
|
- |
|
| Duraibabu Prathyusha |
VP Principal Acct. Officer |
• – – |
2021-02-25 |
4 |
D |
$11.19 |
$20,847 |
D/D |
(1,863) |
27,385 |
|
- |
|
| Markels John |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
13,200 |
|
- |
|
| Meyers James R |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
23,200 |
|
- |
|
| Ramasastry Saira |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
23,200 |
|
- |
|
| Zakrzewski Joseph S |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
48,200 |
|
- |
|
| Carey Robert |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
23,200 |
|
- |
|
| Hillan Kenneth |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
23,200 |
|
- |
|
| Schott Robert J. |
SVP, Head of Development |
• – – |
2021-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
|
- |
|
| Macrae Sandy |
President and CEO |
• • – |
2021-01-24 |
4 |
D |
$14.95 |
$59,456 |
D/D |
(3,977) |
244,002 |
|
- |
|
| Ramelmeier Rolf Andrew |
EVP, Technical Operations |
• – – |
2020-12-31 |
4 |
S |
$16.74 |
$41,247 |
D/D |
(2,464) |
65,978 |
|
- |
|
| Ramelmeier Rolf Andrew |
EVP, Technical Operations |
• – – |
2020-12-24 |
4 |
S |
$18.13 |
$60,391 |
D/D |
(3,331) |
68,442 |
|
- |
|
| Ramasastry Saira |
Director |
– • – |
2020-12-17 |
4 |
S |
$13.27 |
$132,747 |
D/D |
(10,000) |
15,000 |
|
- |
|
| Ramasastry Saira |
Director |
– • – |
2020-12-17 |
4 |
OE |
$5.99 |
$59,900 |
D/D |
10,000 |
25,000 |
|
- |
|
| Lee Sung |
EVP, Chief Financial Officer |
• – – |
2020-11-25 |
4 |
D |
$9.77 |
$49,260 |
D/D |
(5,042) |
88,708 |
|
- |
|
| Hillan Kenneth |
Director |
– • – |
2020-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Business Officer |
• – – |
2020-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
| Boissel Stephane |
EVP, Corp. Strategy |
• – – |
2020-06-04 |
4 |
D |
$11.23 |
$167,406 |
D/D |
(14,907) |
70,116 |
|
- |
|
| Boissel Stephane |
EVP, Corp. Strategy |
• – – |
2020-06-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,907 |
85,023 |
|
- |
|
| Dilly Stephen George |
Director |
– • – |
2020-05-18 |
4/A |
A |
$0.00 |
$0 |
D/D |
10,000 |
15,000 |
|
- |
|
548 Records found
|
|
Page 6 of 22 |
|
|
0.04 (6.83%) 
